secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001689375-25-000004
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts clinical hold on Entrada's ENTR-601-44 for DMD Phase 1b study
-----------------------------------------------------------------------

- FDA authorized ELEVATE-44-102, a Phase 1b multiple ascending dose study of ENTR-601-44 in adults with DMD amenable to exon 44 skipping.
- Study targets ~32 non-ambulatory and ambulatory patients; doses from 0.16 to 1.28 mg/kg every six weeks.
- Company also received UK MHRA authorization for ELEVATE-44-201; global program now covers pediatric and adult patients.
- Plans to initiate enrollment in first half of 2026 with seamless transition to open-label extension.
- CEO cites strength of Phase 1 safety/target engagement data and unmet need in adults living with Duchenne.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937525000004/0001689375-25-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937525000004/trda-20250224.htm
  HTML page:      https://secwatch.observer/filing/0001689375-25-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer